Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Moleculin wraps treatment in first stage of AML trial with $7.3m cash on hand

The US biotech says all 90 Part A patients in its Annamycin study have finished therapy, with data due early 2027 and a small cash balance.

16 Nov 2026 · Moleculin Biotech, Inc. MBRX · Company news

Moleculin Biotech has finished treating the 90 patients in the first stage of its Phase 2/3 MIRACLE study, moving its lead leukaemia candidate closer to the readout that will shape the rest of the programme. The company disclosed the milestone alongside third-quarter 2026 results on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Moleculin Biotech, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →